Onzima Ventures to buy remaining stake in drug discovery company

Maryam Cockar Sharecast | 13 Apr, 2017 09:11 | | |

pills tablets medicine drugs pharmaceutical
  • 1.20
  • -4.00%-0.05
  • Max: 1.20
  • Min: 1.20
  • Volume: 0
  • MM 200 : n/a
17:18 26/04/17
  • 2,060.20
  • 0.27%5.51
  • Max: 2,061.90
  • Min: 2,048.59
  • Volume: 0
  • MM 200 : n/a
17:18 26/04/17
  • 960.14
  • 0.30%2.85
  • Max: 960.14
  • Min: 956.79
  • Volume: 0
  • MM 200 : n/a
17:18 26/04/17

AIM-listed investor Onzima Ventures is to buy the remaining 51% stake it does not already own in N4 Pharma, a drug discovery company, subject to shareholder approval.

At the next general meeting on 2 May, the company will also propose change its name to N4 Pharma, and if approved its ticker will be changed to N4P and its website address to www.n4pharma.com.

The company will pay for the interest with issue of 4.51m new shares and 4,59m deferred shares to be issued after the reorganisation of its shares. The new shares expected to trade on AIM on 3 May.

Onzima has also raised £1.5m from a placing of 21.42m shares at 7p each to fund development of additional patent applications for reformulations of a range of generic drugs, to undertake clinical trials for N4 Pharma's reformulation of sildenafil, the medical name for generic Viagra.

N4 Pharma chief executive Nigel Theobald said: "Bringing a new drug to market is inherently risky, time consuming and extremely costly. However, the established process of reformulating already established drugs reduces the risk, cost and length of time it takes to bring new versions of these drugs to market.

“Following completion of the transaction, the net funds raised will enable N4 Pharma to accelerate its work on the reformulation of generic drugs and those that are coming to the end of their patent protection, each with attractive commercial opportunities, as well as expand our product portfolio.”

More news

26 Apr US close: Markets fall as investors react to Trump tax plan

US stocks were down on Wednesday as investors digested the details of President Donald Trump’s tax reform.

26 Apr Le Pen's long odds attract new punters to French political betting

Gamblers have been piling in to bet on far-right candidate Marine Le Pen wrestling a surprise win over centrist candidate Emmanuel Macron next month, according to bookmakers.

26 Apr Thursday preview: Dovish ECB expected, WPP could turn cautious

The European Central Bank is forecast to leave its main policies unchanged in its meets this week, following a March meeting when the market made a rather hawkish interpretation of the outcome.

26 Apr Commodities: Crude bounces off lows as EIA data shows fall in US inventories

Crude futures bounced off earlier lows on Wednesday afternoon as US Energy Information Administration (EIA) data showed a surprise fall in inventories last week.

26 Apr Twitter shares jump as traffic continues to accelerate in Q1

Twitter continued to be mired in red ink during the first quarter despite continued and accelerating growth of activity on its site, amid revenue headwinds.

26 Apr US open: Stocks little changed as investors eye Trump tax announcement

US stocks were little changed on Wednesday as investors awaited a speech on tax reform by President Donald Trump.

26 Apr Small cap news round-up

Glanbia is to sell a 60% stake in its Irish dairy business, to Glanbia Co-operative Society for €112m.

26 Apr FTSE 250 movers: Aggreko gains ahead of update, Tullow gushes lower

London's FTSE 250 index was up 0.5% to 19,670.48 in afternoon trade.

26 Apr WTI futures spike higher following DoE inventory data

US crude oil inventories fell sharply last week despite rising imports as product stockpiles continued to build.

26 Apr FTSE 100 movers: Standard Chartered rallies on results, GKN drops

London's FTSE 100 was up 0.2% to 7,287.12 in afternoon trade as investors digested comments from US Treasury Secretary Steven Mnuchin, who confirmed that Donald Trump plans to cut corporate tax to 15% from 35%.